



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2015 Certified Company
CIN No. : L24239MH1988PLC047759

SYNCOM/SE/2020-21

14th August, 2020

Online filing at www.listing.bseindia.com

To,
The General Manager
DCS-CRD
BSE Ltd.
Dalal Street, Fort,
MUMBAI-400001

BSE CODE: 524470

Subject: Submission of the Standalone Unaudited Financial Results and Limited Review Report of the Auditors for the Quarter ended 30th June, 2020 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir/Ma'am,

This is in continuation of our letter No. SYNCOM/SE/2020-21 dated 5th August, 2020 regarding intimation of Board meeting for consideration and approval of the Quarterly Standalone Un-audited Financial Results & Limited Review Report thereon, for the Quarter Ended 30th June, 2020.

We are pleased to submit the followings;

1. Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2020 which was considered and approved by the Board at their Meeting held on 14th August, 2020 in accordance with the Regulation 33 of the SEBI (LODR) Regulations, 2015.
2. Limited Review Report given by the Auditors on the Standalone Unaudited Financial Results of the Company for the Quarter Ended 30th June, 2020 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015, which was also considered and approved by the Audit Committee and Board of Directors of the Company at their meeting held on 14th August, 2020.


We are also in process of filing the aforesaid Financial Results in the XBRL format within the stipulated time and the same shall also be hosted at the website of the Company.

The Financial Results will be published in widely circulated English and Marathi Newspapers in the prescribed format.

You are requested to take on record the above said Standalone Un-audited Financial Results & Limited Review Report for your reference and record.

Thanking You,
Yours Faithfully,

For, SYNCOM FORMULATIONS (INDIA) LIMITED


CS SHUBHAM DUBEY
COMPANY SECRETARY &
COMPLIANCE OFFICER



Encl.: Standalone Unaudited Financial Results and Limited Review Report.

Bringing a smile on every face...



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2020

(Rs.In Lakhs) (Except EPS)

S. No.	Particulars	Quarter Ended			Year Ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		Unaudited	Audited*	Unaudited	Audited
1	Revenue from Operations	2924.00	4303.67	5383.92	20551.11
2	Other Income	89.89	157.37	139.76	522.19
3	Total Income (1 + 2)	3013.89	4461.04	5523.68	21073.30
4	EXPENSES				
	(a) Cost of materials consumed	1029.83	2039.99	2662.91	9562.23
	(b) Purchases of Stock-in-Trade	735.07	1258.20	1919.36	5969.46
	(c) Changes in inventories of finished goods, Stock-in- Trade and work-in-progress	82.23	64.81	(594.55)	(369.62)
	(d) Employee benefits expense	341.86	415.28	392.93	1629.26
	(e) Finance costs	3.49	29.71	4.40	46.01
	(f) Depreciation and amortization expense	99.88	101.86	100.41	406.11
	(g) Other expenses	322.87	167.24	629.24	2095.78
	Total expenses (4)	2615.23	4077.09	5114.70	19339.23
5	Profit/(loss) before exceptional items and tax (3- 4)	398.66	383.95	408.98	1734.07
6	Exceptional Items	0.00	(0.22)	0.00	5.16
7	Profit/(loss) before tax (5 - 6)	398.66	384.17	408.98	1728.91
8	Tax expense:				
	(1) Current tax	120.00	103.26	107.60	443.26
	(2) Deferred tax	(17.89)	(69.70)	4.48	(139.70)
9	Profit (Loss) for the period from continuing operations(7-8)	296.55	350.61	296.90	1425.35
10	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00
11	Tax expense of discontinued operations	0.00	0.00	0.00	0.00
12	Profit/(loss) from Discontinued operations(after tax) (10-11)	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9 + 12)	296.55	350.61	296.90	1425.35
14	Other Comprehensive Income				
	A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
	B (i) Items that will be reclassified to profit or loss	36.06	(23.89)	(23.77)	(122.72)
	(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period) (13 + 14)	332.61	326.72	273.13	1302.62
16	Paid up Share Capital of the Company (Face Value 1/-)	7806.52	7806.52	7806.52	7806.52
17	Reserves excluding revaluation reserves	-	-	-	6758.50
18	Earnings per equity share (for continuing operation):				
	(1) Basic	0.04	0.04	0.03	0.17
	(2) Diluted	0.04	0.04	0.03	0.17
19	Earnings per equity share (for discontinued operation):				
	(1) Basic	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing operations)				
	(1) Basic	0.04	0.04	0.03	0.17
	(2) Diluted	0.04	0.04	0.03	0.17

Place: Indore
Date: 14/08/2020

For, Syncom Formulations (India) Limited



Kedarmal Bankda
Chairman & Wholetime Director
DIN: 00023050



SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7,Niraj Industrial Estate,Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759

SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY RESULTS

S. No.	Particulars	Quarter Ended			Year Ended
		30/06/2020	31/03/2020	30/06/2019	31/03/2020
		Unaudited	Audited*	Unaudited	Audited
1	Segment Revenue				
	a) Pharmaceuticals Drugs & Formulations	2525.84	3598.86	3819.65	15997.02
	b) Trading of Commodities	433.11	774.02	1613.68	4742.25
	c) Renting of Property	54.94	88.15	90.35	334.02
	Total Segment Revenue	3013.89	4461.04	5523.68	21073.29
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00
	Revenue from Operations	3013.89	4461.04	5523.68	21073.29
2	Segment Results Profit(+)/Loss(-) before tax and interest from each segment				
	a) Pharmaceuticals Drugs & Formulations	322.63	295.24	287.03	1333.78
	b) Trading of Commodities	24.58	30.27	36.00	112.28
	c) Renting of Property	54.94	88.15	90.35	334.02
	Total Profit before tax	402.15	413.66	413.38	1780.08
	Less: i) Interest	3.49	29.71	4.40	46.01
	ii) Other Un-allocable Expenditure		0.00	0.00	0.00
	Profit before tax	398.66	383.96	408.98	1734.07
3	(Segment Asset-Segment Liabilities)				
	Segment Asset				
	a) Pharmaceuticals Drugs & Formulations	12443.15	12812.41	13002.66	12698.52
	b) Trading of Commodities	493.38	469.66	487.26	583.55
	c) Renting of Property	4780.85	4770.29	4087.55	4770.29
	Total Segment Asset	17717.38	18052.36	17577.47	18052.36
	Un-allocable Assets	0.00	0.00	0.00	0.00
	Net Segment Asset	17717.38	18052.36	17577.47	18052.36
	Segment Liabilities				
	a) Pharmaceuticals Drugs & Formulations	2495.60	3301.51	3904.17	3301.51
	b) Trading of Commodities	146.43	8.13	5.30	8.13
	c) Renting of Property	177.71	177.71	132.48	177.71
	Total Segment Liabilities	2819.74	3487.34	4041.95	3487.34
	Un-allocable Liabilities	0.00	0.00	0.00	0.00
	Net Segment Liabilities	2819.74	3487.34	4041.95	3487.34

Notes:-

- The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14th August, 2020.
- The above financial results are prepared in compliance with Indian Accounting Standard ("IND AS") as notified under section 133 of companies act 2013 ("the Act") [Companies (Indian Accounting Standard) Rules, 2015] as amended
- The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.
- As required under Regulations 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been Completed for the quarter ended 30th June, 2020. The report does not have any impact on the above results and notes which needs explanation.
- Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.
- * The figures of last quarter ended on 31/03/2020 are the balancing figures between audited figures in respect of full financial year.
- The outbreak of COVID-19 has disrupted economic activities across the world. Though, there have been some Operational difficulties due to lock down imposed nationwide, which impact overall operations.

Place: Indore
Date: 14/08/2020

For, Syncom Formulations (India) Limited



Kedarmal Bankda
Chairman & Wholetime Director
DIN: 00023050

SANJAY MEHTA & ASSOCIATES

Chartered Accountants

338, Saket Nagar, Indore - 452 018

Phone/Telefax : 0731-4274391, 2563625

E-mail:sanjaymehta.associates@gmail.com

LIMITED REVIEW REPORT

To,
The Board of Directors of
SYNCOM FORMULATIONS (INDIA) LIMITED
Indore (M.P.)

1. We have reviewed the accompanying statement of unaudited financial results of **Syncom Formulations (India) Limited** for the period ended 30th June, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore
Date: 14/08/2020

For, Sanjay Mehta & Associates
Chartered Accountants
FRN: 011524C


CA Manish Mittal
(Partner)
M. No. 079452
UDIN: 20079452AAAAFD4865

